11:44:28 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-05-12 Ordinarie utdelning ATANA 0.00 SEK
2025-05-09 Kvartalsrapport 2025-Q1
2025-05-09 Årsstämma 2025
2025-02-21 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-03 Kvartalsrapport 2024-Q1
2024-05-03 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-08 Ordinarie utdelning ATANA 0.00 SEK
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-12-07 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning ATANA 0.00 SEK
2022-05-06 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning ATANA 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-05-07 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-11-09 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning ATANA 0.00 SEK
2020-05-08 Kvartalsrapport 2020-Q1
2020-05-08 Årsstämma 2020
2020-02-24 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-08-09 Extra Bolagsstämma 2019
2019-08-07 Kvartalsrapport 2019-Q2
2019-05-08 Ordinarie utdelning ATANA 0.00 SEK
2019-05-07 Kvartalsrapport 2019-Q1
2019-04-05 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-05-08 Ordinarie utdelning ATANA 0.00 SEK
2018-05-07 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriLäkemedel & Handel
Attana bedriver forskning och utveckling av läkemedel. Bolaget specialiserar sig inom biologisk interaktionskarakterisering, som används för analys i utvecklandet av nya läkemedel. Bolagets patenterade lösningar används vid studerandet av bindningsegenskaper och makrostrukturer i celler, proteiner, virus och bakterier. Verksamhet återfinns främst inom Norden och Europa. Bolaget grundades under 2002 och har sitt huvudkontor i Stockholm.
2022-05-18 13:18:23

Attana now enables self sampling through an updated CE IVD-marking for capillary blood samples using Capitainer[®]qDBS cards (quantitative dried blood spot), enabling laboratories improved opportunities to perform immune profiling and monitoring of vaccine efficacy in broad patient populations.

As presented together with Capitainer in February 2022, the goal of Attana Diagnostics is to offer broader and more patient-centric blood sampling solutions for the Attana AVA[TM] system. Since then, Attana has validated its AVA[TM] SARS-CoV-2 IgG Immunoassay kit for capillary blood samples, both qDBS and test tubes. The result of this work has today led to an updated CE IVD-marking.

Attanas CE IVD-marked products
The CE IVD-marked test is a serological immunoassay for the detection of IgG antibodies to SARS-CoV-2 used together with Attana's analytical instruments. In the summer of 2021, the product was initially registered solely for analysis of serum samples. The sample types have now been expanded to also include capillary blood samples (finger prick) both as whole blood in test tubes and via Capitainer[®]qDBS cards (quantitative dried blood spot). The CE IVD-marking still allows qualitative and semi-quantitative measurement of IgG antibodies, but laboratories using the Attana diagnostic platform also have access to unique data (for research use), such as antibody neutralization from the patient samples.

About the studies behind the CE IVD-marking
All technical studies have been performed in Kalmar in collaboration with Linnaeus University. The capillary patient samples were analyzed with Attana's CE IVD-marked kits and validated against serum samples taken at the same time, showing very good agreement. The studies are supplemented by technical studies previously published by Capitainer.

[image]

The attached picture shows the blood sample types which Attana has CE IVD-marked and those which can be used for research purposes ("Research use").

Teodor Aastrup, CEO of Attana, comments:
"By expanding our product offering with self sampling together with the Capitainer[®]qDBS cards, Attana now enables distributed, simple, and quality-assured sampling for information-rich immunity profiling."